It could also be deduced that miR-142-3p targeting RhoBTB3 bound to TGFβR1 participating in ligand-activated transcription factor (for instance, TGFβ) pathways underlying tumor progression or with CLOCK participating in tumor radiochemotherapy resistance (especially in KIRC). This evidence concerns the gene TGFBR1 and neoplasm.